CNE100002RG2
CNE100002RG2
DASHENLIN PHARMACEUTICAL GROUP
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 27.502.188.411 | 26.496.547.002 | 3.8% |
| Cost of Revenue | 18.064.052.811 | 17.401.139.013 | 3.8% |
| Gross Profit | 9.438.135.600 | 9.095.407.989 | 3.8% |
| 7.342.943.516 | 7.483.283.243 | 1.9% | |
| Operating Income | 2.095.192.085 | 1.612.124.746 | 30.0% |
| Pretax Income | 1.849.447.594 | 1.339.672.690 | 38.1% |
| Net Income Common Stockholders | 1.235.246.215 | 914.754.951 | 35.0% |
| -- | -- | -- | |
| -- | -- | -- |